Scarica l'app Stockscreener
0.00
100.00%
-8.68
Dopo l'orario di chiusura:
8.69
8.69
+
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché SAGE Giù?
Forum
Previsione
Precedente Chiudi:
$8.68
Aprire:
$0
Volume 24 ore:
0
Relative Volume:
0.00
Capitalizzazione di mercato:
$544.94M
Reddito:
$91.06M
Utile/perdita netta:
$-503.14M
Rapporto P/E:
0.00
EPS:
-8.39
Flusso di cassa netto:
$-424.74M
1 W Prestazione:
-100.00%
1M Prestazione:
-100.00%
6M Prestazione:
-100.00%
1 anno Prestazione:
-100.00%
Intervallo 1D:
$0.00
$0.00
Intervallo di 1 settimana:
$0.00
$0.00
Portata 52W:
$0.00
$9.36
Sage Therapeutics Inc Stock (SAGE) Company Profile
Nome
Sage Therapeutics Inc
Settore
Industria
Telefono
617-299-8380
Indirizzo
55 CAMBRIDGE PARKWAY, CAMBRIDGE, MA
Confronta SAGE con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SAGE
Sage Therapeutics Inc
|
0.00 | 544.94M | 91.06M | -503.14M | -424.74M | -8.39 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.46 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
598.16 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
467.55 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
663.73 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.97 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Sage Therapeutics Inc Stock (SAGE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-03-11 | Ripresa | BofA Securities | Underperform |
| 2024-11-21 | Aggiornamento | RBC Capital Mkts | Underperform → Sector Perform |
| 2024-10-10 | Ripresa | Raymond James | Mkt Perform |
| 2024-10-04 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-07-30 | Downgrade | TD Cowen | Buy → Hold |
| 2024-07-25 | Downgrade | JP Morgan | Overweight → Neutral |
| 2024-05-29 | Iniziato | Citigroup | Sell |
| 2024-05-29 | Iniziato | Robert W. Baird | Neutral |
| 2024-04-17 | Downgrade | BofA Securities | Neutral → Underperform |
| 2023-12-12 | Iniziato | Deutsche Bank | Hold |
| 2023-08-08 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2023-08-08 | Downgrade | Goldman | Buy → Neutral |
| 2023-08-08 | Downgrade | Needham | Buy → Hold |
| 2023-08-07 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-08-07 | Downgrade | Oppenheimer | Outperform → Perform |
| 2023-08-07 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-08-07 | Downgrade | Stifel | Buy → Hold |
| 2023-08-07 | Downgrade | Wedbush | Outperform → Neutral |
| 2023-07-27 | Iniziato | Scotiabank | Sector Outperform |
| 2023-03-13 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-01-03 | Downgrade | Guggenheim | Buy → Neutral |
| 2022-11-01 | Iniziato | Loop Capital | Hold |
| 2022-03-31 | Iniziato | Berenberg | Hold |
| 2021-11-02 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2021-10-19 | Ripresa | Morgan Stanley | Equal-Weight |
| 2021-10-07 | Downgrade | Jefferies | Buy → Hold |
| 2021-09-23 | Iniziato | Needham | Buy |
| 2021-06-16 | Downgrade | Citigroup | Buy → Neutral |
| 2021-04-07 | Iniziato | Piper Sandler | Overweight |
| 2021-02-26 | Downgrade | Mizuho | Buy → Neutral |
| 2021-02-25 | Reiterato | H.C. Wainwright | Neutral |
| 2021-02-02 | Ripresa | Raymond James | Mkt Perform |
| 2021-01-22 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2021-01-04 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2021-01-04 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-12-04 | Aggiornamento | Mizuho | Neutral → Buy |
| 2020-12-01 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2020-11-16 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-11-06 | Reiterato | H.C. Wainwright | Neutral |
| 2020-09-11 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2020-08-10 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2020-05-08 | Downgrade | Wedbush | Outperform → Neutral |
| 2020-04-08 | Downgrade | Guggenheim | Buy → Neutral |
| 2020-03-18 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-03-06 | Iniziato | Citigroup | Buy |
| 2020-02-28 | Reiterato | H.C. Wainwright | Neutral |
| 2020-02-06 | Iniziato | Mizuho | Neutral |
| 2019-12-06 | Reiterato | RBC Capital Mkts | Outperform |
| 2019-12-05 | Reiterato | Guggenheim | Buy |
| 2019-12-05 | Downgrade | SunTrust | Buy → Hold |
| 2019-10-30 | Iniziato | H.C. Wainwright | Neutral |
| 2019-05-23 | Iniziato | Wedbush | Outperform |
| 2019-04-25 | Iniziato | Jefferies | Buy |
| 2018-12-14 | Iniziato | Wolfe Research | Outperform |
| 2018-10-11 | Iniziato | Oppenheimer | Outperform |
Mostra tutto
Sage Therapeutics Inc Borsa (SAGE) Ultime notizie
Published on: 2025-08-21 00:14:22 - thegnnews.com
Sage Therapeutics Inc. Enters Reversal Setup in Weekly ChartsMarket Activity Recap & Fast Entry Momentum Trade Alerts - newsyoung.net
Layoff Tracker: Bausch Health Closes California Site, Cuts 49 Employees - BioSpace
Postpartum Depression Market to Witness Promising Upswing by 2034, DelveInsight Forecasts | SAGE Therapeutics, Brii Biosciences Limited, Reunion Neuroscience, GH Research, Bristol-Myers Squibb - Barchart.com
What is the long term forecast for Sage Therapeutics Inc. stockLong Setup & Risk Adjusted Buy and Sell Alerts - thegnnews.com
Can Sage Therapeutics Inc. be recession proofStocks with Huge Upside Movement - thegnnews.com
SUPERNUS PHARMACEUTICALS, INC. SEC 10-Q Report - TradingView
Supernus Pharmaceuticals Announces Q2 2025 Financial Results and Acquisition of Sage Therapeutics - Quiver Quantitative
Supernus Announces Second Quarter 2025 Financial Results - GlobeNewswire
MACD Cross Could Confirm Trend in Sage Therapeutics Inc.Profit Focused Stock Screener Results Released - beatles.ru
Sage Therapeutics (NASDAQ:SAGE) Rating Increased to Hold at Wall Street Zen - MarketBeat
Is it the right time to buy Sage Therapeutics Inc. stockUnlock powerful market trend analysis - Jammu Links News
How volatile is Sage Therapeutics Inc. stock compared to the marketConsistently high returns - Jammu Links News
What is the dividend policy of Sage Therapeutics Inc. stockHigh-octane financial growth - Jammu Links News
Is Sage Therapeutics Inc. a growth stock or a value stockGet alerts on high-potential stock breakouts - Jammu Links News
Why is Sage Therapeutics Inc. stock attracting strong analyst attentionCapitalize on market shifts with expert advice - Jammu Links News
What are the latest earnings results for Sage Therapeutics Inc.Free Investment Timing Strategies - Jammu Links News
How strong is Sage Therapeutics Inc. company’s balance sheetGet daily expert analysis on top stocks - Jammu Links News
When is Sage Therapeutics Inc. stock expected to show significant growthStrongest growth potential - Jammu Links News
What institutional investors are buying Sage Therapeutics Inc. stockExtraordinary market timing - Jammu Links News
What are Sage Therapeutics Inc. company’s key revenue driversCapitalize on high-yield stock opportunities - Jammu Links News
What makes Sage Therapeutics Inc. stock price move sharplyHigh-velocity gains - Jammu Links News
Supernus Acquires Sage Therapeutics to Strengthen Neuropsychiatric Portfolio - AInvest
Sage (SAGE) Q2 Revenue Jumps 264% - AOL.com
Analysts Offer Insights on Healthcare Companies: SAGE Therapeutics (SAGE) and ZimVie Inc (ZIMV) - The Globe and Mail
Supernus strengthens neuropsychiatric portfolio with Sage Therapeutics - Yahoo Finance
SAGE Therapeutics Announces Nasdaq Delisting Following Merger and Board Changes - AInvest
Today's SEC FilingsLatest 10-K, 10-Q, 8-K Forms - Stock Titan
Huntington’s Disease Market to Expand Significantly by 2034, States DelveInsight Report | Prilenia Therapeutics, Neurocrine Biosciences, Som Biotech, Annexon Biosciences, Vaccinex, Sage Therapeutics - Barchart.com
Supernus completes acquisition of Sage Therapeutics for $8.50 per share By Investing.com - Investing.com Nigeria
Supernus completes acquisition of Sage Therapeutics for $8.50 per share - Investing.com Australia
Supernus Pharmaceuticals Completes Acquisition of Sage Therapeutics - GlobeNewswire
Supernus Pharmaceuticals Acquires Sage Therapeutics to Strengthen Presence in Neuropsychiatric Conditions - AInvest
Supernus' $200M Sage Therapeutics Acquisition Adds First-Ever Oral Postpartum Depression Drug - Stock Titan
Sage Therapeutics 2025 Q2 Earnings Significant Revenue Growth as Net Income Loss Narrows 51.7% - AInvest
Sage Therapeutics Announces Second Quarter 2025 Financial Results - BioSpace
SAGE Therapeutics earnings beat by $0.15, revenue topped estimates - Investing.com Canada
Sage Therapeutics, Inc. (SAGE) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
Sage Therapeutics Announces Second Quarter 2025 Financial Results | SAGE Stock News - GuruFocus
Market reaction to Sage Therapeutics Inc.’s recent newsWeekly Stock Opportunity Radar Scanner Activated - metal.it
Supernus Pharmaceuticals Announces Expiration of HSR Waiting Period for Sage Therapeutics Acquisition - AInvest
Sage Therapeutics Acquisition Advances Amid Antitrust Review Expiration and Analyst Forecasts - AInvest
Cwm LLC Buys 58,410 Shares of Sage Therapeutics, Inc. (NASDAQ:SAGE) - MarketBeat
Published on: 2025-07-29 04:12:23 - metal.it
Supernus Pharmaceuticals Announces Expiration of - GlobeNewswire
Supernus announces expiration of HSR waiting period for Sage Therapeutics - TipRanks
SAGE Acquisition Advances as Antitrust Waiting Period Ends - GuruFocus
Supernus Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Sage Therapeutics, Inc. Tender Offer - The Manila Times
Supernus Pharmaceuticals Announces Expiration of HSR Waiting Period for Acquisition of Sage Therapeutics - Quiver Quantitative
Sage Therapeutics Inc Azioni (SAGE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.55%
0.38%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):